Rani Therapeutics collaborates with MedImmune in the metabolic disease field

Rani Therapeutics has entered into a collaboration with MedImmune, the global biologics R&D arm of Anglo-Swedish pharma major AstraZeneca (LSE: AZN), to evaluate Rani's novel oral drug delivery platform.

The companies have agreed to conduct feasibility studies over the next two years, in which Rani – dubbed the “robotic pill maker” - will test select biologic molecules in the area of metabolic disease to evaluate the oral delivery of these molecules.

On successful completion of the feasibility studies, AstraZeneca and MedImmune will have the right to enter into a more extensive collaboration with Rani.